Lymphoproliferative disorders can be pretty serious, as they mean your immune system doesn't work the way it should. They can ...

Chronically immunocompromised patients have a markedly increased risk of developing lymphoproliferative ... Kaposi's sarcoma (KS), Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL).

CMC-544 has high efficacy in combination with rituximab for follicular lymphoma (FL) and diffuse large B-cell lymphoma, at the expense of moderate toxicity. BL22 and HA22 have high durable ...

and lymphomas in immunosuppressed patients after organ transplant (post-transplant lymphoproliferative disorders or PTLD). My Role at MSK A lymphoma specialist is a doctor with special training in ...

EBViously, a spin-off of Helmholtz Munich, officially started operations on 11 November 2024. The company is developing a ...

Further evaluation of the antitumor activity of the triple variant in B-lymphoma cells and rituximab ... treatment for human B-cell lymphoproliferative disorders. “In conclusion, the rituximab ...

EBV latency has been classified into three types: type I (Burkitt's lymphoma), in which only ... and type III (lymphoproliferative diseases in immunosuppressed individuals), in which five EBNAs ...